Drug Trial Radar · NCT01892137
Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
137
Actual
Start
Jul 2013
Primary completion
Mar 2014
Study completion May 2014
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 4, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this trial is to demonstrate the predictive value of the clinical diagnosis of clearance of Actinic Keratoses after treatment with Ingenol Mebutate using histopathological examination as the standard.
Conditions
- Actinic Keratosis
Interventions
Ingenol mebutate gel 0.05%Drug
Once daily for 2 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clearance of AKTime frame: 8 weeks
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Southderm Pty Ltd
Kogarah, New South Wales, Australia
Melanoma Institute Australia
North Sydney, New South Wales, Australia
The Skin Centre
Benowa, Queensland, Australia
South East Dermatology Centre
Carina Heights, Queensland, Australia
St John of God Dermatology
Subiaco, Western Australia, Australia
Burswood Dermatology
Victoria Park, Western Australia, Australia
Klinik für Dermatologie & Allergologie Klinikum Augsburg Süd
Augsburg, Germany
Collegium Medicum Berlin GmbH
Berlin, Germany
Medizinisches Zentrum Bonn Friedensplatz
Bonn, Germany
Hautarztpraxis Prof. Dr. med. C. Termeer
Stuttgart, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.